molnupiravir - International Biopharmaceutical Industry

Current Edition

news

New Merck study results raise questions about its COVID pill

Final trial data for molnupiravir were less convincing than what Merck previously reported and could alter how the FDA views the drug. New study results disclosed by...

3 December 2021 news COVID-19 pill | Food and Drug Administration

Continue Reading →

news

Merck agrees to license COVID-19 pill widely through pact with patent group

Merck's pill has the potential to alter the course of the pandemic. Earlier this month, the company and partner Ridgeback Biotherapeutics released data showing molnup...

29 October 2021 news COVID-19 | COVID-19 pill

Continue Reading →

news

Gates Foundation pledges $120M to bring Merck COVID-19 drug to lower-income countries

The Gates Foundation hopes to reduce the gap in time between when wealthy countries and lower-income nations get access to needed medicines like molnupiravir. The fou...

22 October 2021 news COVID-19 | Gates Foundation

Continue Reading →

news

Merck, Ridgeback seek US clearance of first oral COVID-19 drug

Merck’s filing comes less than two weeks after the drugmaker showed molnupiravir lowered the risk of hospitalization or death by roughly 50% in a Phase 3 trial, a res...

15 October 2021 news clinical trial | COVID-19

Continue Reading →

International Biopharmaceutical Industry

IBI – International Biopharmaceutical Industry was established to fill in the void for effective marketing and communication between all stakeholders in the Life sciences sector globally.

Current Edition

Upcoming Events

Advertisement

New Merck study results raise questions about its COVID pill

Merck agrees to license COVID-19 pill widely through pact with patent group

Gates Foundation pledges $120M to bring Merck COVID-19 drug to lower-income countries

Merck, Ridgeback seek US clearance of first oral COVID-19 drug

International Biopharmaceutical Industry